PA5-49715

antibody from Invitrogen Antibodies

Targeting: FGF7 KGF

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-49715

Provider

Invitrogen Antibodies

Product name

KGF Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

The antibody detects endogenous level of total FGF7 protein.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.4 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

FGF7-induced E11 facilitates cell-cell communication through connexin43.

Liu X, Bai M, Sun Y, Hu X, Wang C, Xie J, Ye L
International journal of biological sciences 2021;17(14):3862-3874

---

Efficient Surface Immobilization of Chemically Modified Hyaluronans for Enhanced Bioactivity and Survival of In Vitro-Cultured Embryonic Salivary Gland Mesenchymal Cells.

Lee SW, Kim J, Cong X, Yu GY, Ryu JH, Park K
Polymers 2021 Apr 9;13(8)

---

microRNA-155 inhibition restores Fibroblast Growth Factor 7 expression in diabetic skin and decreases wound inflammation.

Moura J, Sørensen A, Leal EC, Svendsen R, Carvalho L, Willemoes RJ, Jørgensen PT, Jenssen H, Wengel J, Dalgaard LT, Carvalho E
Scientific reports 2019 Apr 9;9(1):5836

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 ( a ) Bright-field images of E13 eSMGs cultured for 48 h in control, solubilized HA-CA (HA-CA (Sol) ), HA-CA-coated surfaces (HA-CA (Co) ), and hyaluronidase-treated HA-CA-coated surfaces (HA-CA (Co/HAD) ). Scale bar = 200 um ( n = 4). ( b ) Bud number fold changes (48 h/0 h) of eSMGs cultured in each group ( n = 4). ( c - e ) mRNA expression level of ( c ) EGF, ( d ) FGF7, and ( e ) FGF10 in eSMGs cultured for 48 h under each condition ( n = 3). ( f ) Immunofluorescence images of mesenchymal EGF (green) and FGF7 (red) expression in eSMGs cultured for 48 h on control and HA-CA-coated surface. DAPI (blue). Scale bar = 50 um ( n = 3). Quantification of mesenchymal ( g ) EGF and ( h ) FGF7 expression based on the immunofluorescence images. Control (gray) and HA-CA (Co) (red) ( n = 4). Data are expressed as average +- SEM ( Figure 4 b-h). ** p < 0.01, **** p < 0.001, ns = non-significant ( p > 0.05) by unpaired t -test ( Figure 4 g,h) and one-way ANOVA with Dunnett''s test ( Figure 4 b-e).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 The high expression of Fgf7 of osteoblasts and the distribution of FGF7 in bone tissue. (A) RNA sequencing results showing the whole fibroblast growth factor family members and receptor members of primary osteoblasts. The data were presented as log (FPKM + 1) and showed the higher mRNA expression of Fgf7 among other FGF ligand members. FPKM: Fragments per Kilobase of transcript per Million fragments mapped. The results were based on three independent samples (n = 3). (B) IHC showing the distribution of FGF7 in the femur of 4 weeks wild-type C57 mice. Fast green is used to counterstain the background. Boxed areas further showing that FGF7 is partly generated by osteoblasts on the surface of trabecular bone within the secondary ossification center (boxed area 1) and subchondral bone (boxed area 2).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 7 Topical administration of miR-155 inhibitor restores FGF7 expression. ( A ) Representative images of FGF7 protein expression assessed by fluorescence microscopy on mouse wound skin tissue of non-diabetic (n = 4) and diabetic mice treated with Neg. Ctrl. oligo (control, n = 3), 2.5 nmol of miR-155 inhibitor (n = 3) or 2.5 nmol of Seed miR-155 inhibitor (n = 3), collected at day 10 post-wounding. Seed miR-155 inhibitor: LNA-oligonucleotides binding to seed region of miR-155. Blue - DAPI, Green - FGF7. ( B ) Quantification of FGF7 expression. Data are presented as mean +- SD of the percentage of non-diabetic condition. Data were analyzed using one-way ANOVA with Dunnet's post hoc correction; **p < 0.01, ***p < 0.001 vs non-diabetic.